ArticleThe Permanente journal2026
Anticoagulant Use and Frequency of Vascular Access Thrombosis: A Retrospective Cohort Study.
Article in The Permanente journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHemodialysis (HD) patients with arteriovenous fistula (AVF) or arteriovenous graft (AVG) are often prescribed anticoagulation to prevent thrombosis, though evidence supporting this practice is limited. This study aimed to compare AVF and AVG thrombosis rates in HD patients with and without anticoagulation to inform clinical practice.
methodsThe authors conducted a retrospective analysis within Kaiser Permanente Northern California, an integrated health care system serving 4.6 million members. Patients initiating HD between January 1, 2013, and December 31, 2021, were identified and categorized based on anticoagulation use after dialysis initiation. Thrombosis rates of AVF and AVG were assessed within 1 year.
resultsA total of 9079 HD patients were included; 1837 received anticoagulation for various indications, 7242 did not. Compared to non-users, the anticoagulation cohort was older, had higher Charlson comorbidity scores, greater prevalence of hypertension and peripheral vascular disease, and lower aspirin use. After 1 year, AVF thrombosis rates were similar between groups. However, AVG thrombosis and bleeding events were more frequent among anticoagulated patients. No substantial differences in thrombosis or bleeding outcomes were observed between warfarin and apixaban users.
conclusionAnticoagulation in HD patients did not reduce AVF or AVG thrombosis and was associated with increased bleeding risk. These findings may reflect differences in baseline patient characteristics. Randomized prospective studies are needed to clarify the role of anticoagulation in maintaining vascular access patency.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.